ArticleAmerican journal of translational research2023
Huangqi Guizhi Wuwu decoction improves hemorheology and inhibits inflammatory response after PCI for acute myocardial infarction.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- Effectiveness and safety of Chinese herbal footbaths as an adjuvant therapy for dysmenorrhea: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Herbal Formula AC591 Protects Against Cisplatin-Induced Hearing Loss by Inhibiting p53-Mediated Ferroptosis.Smart medicine · 2026Article
- Huangqi Guizhi Wuwu decoction ameliorates myocardial damage in ovariectomized rats by regulating the structure and function of myocardial microvessels and intestinal flora.Microbiology spectrum · 2025Article
- Huangqi Guizhi Wuwu decoction promoted the osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ESR1.Cytotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the impact of Huangqi Guizhi decoction of five ingredients on hemorheology and inflammatory factors in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).
methodsA total of 111 cases of AMI treated in Tongchuan Hospital of Traditional Chinese Medicine from February 2019 to February 2022 were analyzed retrospectively. Among them, 47 patients who received routine treatment were assigned to the control group, while those who received Huangqi Guizhi decoction of five ingredients in addition to the treatment of the control group were assigned to the study group. The clinical efficacy in the two groups was evaluated after therapy. The two groups were compared as to changes in serum inflammatory factors [tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6)] before and after therapy. The two groups were also compared as to differences in fibrinogen, plasma viscosity, whole blood low-shear viscosity (WBLSV), and whole blood high-shear viscosity (WBHSV) before and after therapy. Left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic diameter (LVESD), and left ventricular ejection fraction (LVEF) in the two groups were evaluated. In addition, the two groups were compared as to incidence of major adverse cardiovascular events (MACE) in 6 months. Logistic regression analysis was conducted to analyze the risk factors for MACE.
resultsThe study group showed a significantly higher treatment efficacy than the control group (P < 0.05). After therapy, the study group had significantly lower levels of TNF-α, hs-CRP, IL-6, fibrinogen, plasma viscosity, WBLSV, and WBHSV than the control group (all P < 0.05), and showed lower LVEDD and LVESD levels and a higher LVEF level than the control group. According to logistic regression analysis, age, history of diabetes mellitus (TM), New York Heart Association (NYHA) classification, hsCPR, and LVEF were independent risk factors for MACE (all P < 0.05).
conclusionHuangqi Guizhi decoction of five ingredients contributes to higher efficacy in AMI and has the effects of inhibiting the inflammation and hemorheology of patients. In addition, age, history of TM, NYHA classification, hsCPR, and LVEF were independent risk factors for MACE.
Indexed as
Identifiers
37303648PMC10250998W4380291209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.